Clinical Guides
Lung Cancer
A clinically focused guide to suspected lung cancer in India, covering symptom-led diagnosis, TB-aware differential reasoning, efficient tissue and stage acquisition, biomarker-directed multidisciplinary care, oncological emergencies and jurisdiction limits.
MedNext Academy | 14 min read
Lung Cancer
A clinically focused guide to suspected lung cancer in India, covering symptom-led diagnosis, TB-aware differential reasoning, efficient tissue and stage acquisition, biomarker-directed multidisciplinary care, oncological emergencies and jurisdiction limits.
Summary
Lung cancer is a malignant tumour arising in the lung or bronchial epithelium. The clinically important division is between non-small-cell lung cancer, which includes adenocarcinoma, squamous carcinoma and other subtypes, and small-cell lung cancer, which usually has a different tempo and treatment pathway. Histology alone is no longer enough for many patients: anatomical stage, performance status, comorbidity, tumour molecular profile, immune biomarkers and the person's priorities all influence treatment. A radiological mass is not synonymous with primary lung cancer, and treatment should not begin from imaging alone when safe tissue confirmation is feasible.
Possible presentations include persistent or changing cough, haemoptysis, breathlessness, chest or shoulder pain, recurrent or non-resolving pneumonia, hoarseness, unexplained weight loss, fatigue, clubbing, lymphadenopathy or an incidental imaging abnormality. Metastatic or paraneoplastic disease may present with bone pain, neurological symptoms, hyponatraemia, hypercalcaemia or proximal weakness. Smoking is the leading preventable cause, but lung cancer occurs in never-smokers; dismissing symptoms because a person never smoked is unsafe.
The diagnostic pathway aims to obtain the most informative and least harmful sample while establishing stage efficiently. Contrast-enhanced CT generally precedes biopsy planning. Bronchoscopy, endobronchial ultrasound, image-guided percutaneous biopsy or sampling of an accessible metastatic site is chosen according to lesion location and what result will alter management. Treatment may involve surgery, radiotherapy, cytotoxic chemotherapy, targeted therapy, immunotherapy and supportive or palliative interventions. This guide is educational, remains reviewed and has been reviewed by the MedNext Clinical Team, and cannot select a biopsy route, interpret molecular variants or prescribe treatment for an individual.
How Common Is It?
Lung cancer is a major cause of cancer death globally. WHO's April 2026 fact sheet reports an estimated 2.5 million new cases and 1.8 million deaths worldwide in 2022, and describes lung cancer as the leading global cause of cancer death. Those are global estimates and should not be relabelled as Indian totals. The IARC GLOBOCAN 2022 India fact sheet estimated 58,970 new lung-cancer cases among Indian men, ranking lung cancer second among male cancer sites and representing 8.5% of estimated male cancer incidence. The front-page table does not supply a corresponding female top-five count, so this guide does not invent one or infer a combined-sex total.
These figures are modelled estimates built from available registry and mortality information. India's population size, uneven registry coverage, changing tobacco patterns, household and outdoor air pollution, occupational exposures, age distribution and regional variation make a single national number an incomplete description. Histological patterns also differ by sex and smoking exposure. Hospital series cannot be treated as population incidence because referral selection and stage mix distort them.
For clinical work, prevalence statistics must not become a triage score. A person with haemoptysis, persistent focal symptoms or a non-resolving radiographic abnormality needs evaluation even when young or a never-smoker. Conversely, most coughs are not cancer, particularly in a country with a large infectious respiratory burden. For service planning, timely access to CT, bronchoscopy or image-guided biopsy, pathology, molecular testing, thoracic surgery, radiotherapy and systemic treatment determines whether early detection can improve outcomes. Report burden with year, sex and denominator, and use local registry data where available.
Risk Factors
Combustible tobacco smoking is the dominant preventable risk factor, and risk relates to intensity, duration and time since cessation. Ask about cigarettes, bidis, cigars, pipes and other smoked products in a non-judgemental way, documenting current status and approximate cumulative exposure without implying a threshold below which cancer is impossible. Second-hand tobacco smoke also matters. Smoking cessation is worthwhile after suspicion or diagnosis because it can reduce perioperative and treatment complications and improve general health; Current guidelines advises cessation promptly but not delaying indicated lung-cancer surgery simply to create a preoperative abstinence interval.
Other recognised risks include radon, outdoor and household air pollution, occupational asbestos, silica and diesel exhaust, and certain other workplace carcinogens. Take an occupational history that names jobs, materials, duration, ventilation and protective measures rather than asking only whether exposure occurred. Previous thoracic radiotherapy, chronic lung disease and genetic susceptibility may alter risk. Tuberculosis-related scarring and cancer can coexist, but scar on an image should not be assumed to be either causal or benign. Never-smoker lung cancer is biologically important and may carry actionable molecular alterations; the absence of smoking exposure should increase diagnostic precision, not reduce urgency.
Risk assessment also prepares for treatment. Evaluate pulmonary reserve, cardiovascular disease, renal and hepatic function, autoimmune disease, frailty, cognition, nutrition, hearing, neuropathy and previous malignancy. Review medicines, anticoagulation, corticosteroids and supplements. Performance status should reflect the person's usual function and reversible problems rather than age alone. Social risks include travel distance for daily radiotherapy, inability to return for serial infusions, oxygen access, loss of wages and stigma associated with smoking. Prevention focuses on tobacco control and exposure reduction, but no vitamin, supplement, chest radiograph schedule or symptom questionnaire guarantees prevention.
Diagnosis
History
Clarify onset, trajectory and effect of cough, haemoptysis, breathlessness, chest pain, hoarseness, wheeze, fever, recurrent infection, fatigue and weight loss. Ask about volume and recurrence of haemoptysis and symptoms of anaemia or airway compromise. Elicit headache, seizure, focal weakness, confusion, bone pain, pathological fracture symptoms, facial or arm swelling, dysphagia and constitutional change. Record tobacco and occupational exposure, tuberculosis history and tests, prior malignancy, thoracic imaging, lung disease, anticoagulants, performance status and what diagnostic procedures the person could tolerate.
Examination
Assess physiological stability first. Record oxygenation, respiratory effort, haemodynamics, weight and functional status. Examine for lymph nodes that may offer a safer diagnostic site, clubbing, cachexia, Horner syndrome, signs of superior vena cava obstruction, pleural effusion, focal collapse or consolidation, stridor and recurrent laryngeal nerve palsy. Look for hepatomegaly, bony tenderness, focal neurological deficit and endocrine or neuromuscular paraneoplastic signs. A normal chest examination does not exclude a central or peripheral tumour.
Investigations
Initial imaging depends on presentation, but persistent suspicion requires definitive cross-sectional assessment rather than repeated empirical antibiotics. Current guidelines recommends contrast-enhanced CT of the chest including liver, adrenals and lower neck for known or suspected lung cancer, with renal-risk precautions, before selecting invasive tests. Plan sampling to provide diagnosis and stage with the fewest procedures: bronchoscopy for appropriate central lesions, endobronchial ultrasound-guided nodal sampling, CT-guided peripheral biopsy, pleural fluid or biopsy, or an accessible metastatic site. PET-CT and brain imaging are stage- and treatment-intent dependent. Pathology distinguishes NSCLC from SCLC and more specific subtype; adequate material must be preserved for validated molecular and immune-biomarker testing. Multidisciplinary review resolves discordant imaging, microbiology and pathology.
Differential Diagnosis
Pulmonary tuberculosis is a central differential in India, but the correct response is parallel evidence gathering, not automatic anti-tuberculous treatment. Tuberculosis and cancer can coexist; constitutional symptoms, cavitation, nodules and lymphadenopathy overlap. Obtain microbiological samples when infection is plausible and pursue tissue or interval imaging according to the cancer risk and radiological pattern. Failure to respond to treatment, atypical evolution or absent microbiological support should trigger prompt reassessment. Other infections include bacterial lung abscess, fungal disease and non-tuberculous mycobacteria, especially in immunocompromised people.
Benign and inflammatory mimics include rounded atelectasis, organising pneumonia, sarcoidosis, rheumatoid nodules, granulomatosis with polyangiitis, pulmonary infarction and post-inflammatory scar. Hamartoma is a common benign pulmonary neoplasm, but imaging characteristics and growth history determine confidence. A solitary pulmonary nodule is a radiological description, not a diagnosis. Metastasis from another primary tumour can produce one or many lung lesions; prior cancer history changes probability but does not prove origin. Lymphoma and pleural mesothelioma require different pathological framing.
Symptoms also overlap with COPD, asthma, bronchiectasis, heart failure and pulmonary embolism. Massive haemoptysis, hypoxia or haemodynamic compromise is managed as an emergency while cause is investigated. Cytology or a small crushed biopsy can create histological uncertainty; inadequate material should be acknowledged, not over-interpreted. If radiology suggests progression but one sample is negative, review whether the correct lesion was sampled and whether necrosis or sampling error is likely. Conversely, granulomatous inflammation should not be called malignancy. Clinical-radiological-pathological-microbiological concordance is the safe endpoint.
Management
Every confirmed case should be discussed in a multidisciplinary setting able to integrate thoracic radiology, pathology, respiratory medicine, thoracic surgery, radiation oncology, medical oncology and supportive care. The first distinctions are NSCLC versus SCLC, anatomical extent, potential for curative treatment and fitness for each modality. For early NSCLC, anatomical resection with systematic nodal staging is a core curative option when physiology permits. Sublobar resection or stereotactic ablative radiotherapy may be considered in selected disease or when lobectomy is unsuitable. The operation is not chosen from tumour diameter alone; cardiopulmonary reserve, nodal status, location and patient preference matter.
Locally advanced NSCLC may require combinations of chemotherapy, radiotherapy, surgery or immunotherapy in a sequence defined by resectability and current evidence. Advanced NSCLC treatment depends on histological subtype, actionable molecular alterations, immune biomarker results, prior therapy, symptoms and access. Adequate diagnostic tissue is therefore part of treatment quality. SCLC is generally managed with stage-aware systemic therapy and radiotherapy rather than routine surgery, although very limited disease requires expert discussion. Prophylactic or therapeutic brain-directed strategies are individualized and should not be reduced to a memorised rule.
Supportive care begins at diagnosis. Treat pain, breathlessness, cough, haemoptysis, nutrition problems, anxiety and sleep disturbance; drain or manage symptomatic pleural effusion when indicated; and involve palliative care alongside disease-directed treatment. Smoking cessation support is offered without blame. Rehabilitation and prehabilitation can improve function, but must not delay urgent cancer care. Treatment intent, expected benefit, uncertainty, toxicity, visit burden and cost should be documented. Where molecular testing or a drug is unavailable, the tumour board should state the resource constraint and formulate the safest evidence-based alternative rather than imply that a theoretical option is accessible.
Prescribing Information
Systemic lung-cancer treatment must be prescribed within an oncology protocol after verified histology, stage and biomarker assessment. Record treatment intent, performance status, weight and body surface area where relevant, renal and hepatic function, blood counts, hearing and neuropathy risks, autoimmune history, pulmonary comorbidity, infection, medicines, allergies and prior treatment. Confirm pregnancy possibility and reproductive counselling. The drug, dose, route, schedule, dose modifications, hydration, antiemesis and laboratory thresholds require product- and regimen-specific verification; no category statement in this guide substitutes for that process.
Platinum chemotherapy can cause marrow suppression, nausea, kidney injury, electrolyte loss, neuropathy or hearing toxicity, with profiles differing between agents. Other cytotoxics have drug-specific pulmonary, mucosal, neurological or haematological risks. Targeted therapy requires an actionable alteration demonstrated by a validated assay and has agent-specific interactions and organ toxicities. Immune-checkpoint therapy can cause pneumonitis, colitis, hepatitis, endocrinopathy, nephritis, myocarditis or neurological inflammation. New cough or dyspnoea during treatment therefore has a broad differential including infection, progression, embolism, radiation injury and immune toxicity; empirical self-treatment is unsafe.
Patients receiving systemic therapy need written fever and emergency instructions and a 24-hour contact pathway. Suspected neutropenic sepsis is assessed immediately under the institution's protocol. Review anticoagulants, acid-suppressing medicines, anticonvulsants, corticosteroids, herbal products and tobacco-use medicines for interactions. Antiresorptive drugs, analgesics, corticosteroids, antiemetics, growth factors and antimicrobial prophylaxis require defined indications and monitoring. Opioids can relieve cancer pain and breathlessness when prescribed and reviewed carefully; constipation and sedation prevention matter. Safe prescribing also includes pharmacy verification, infusion-reaction readiness, extravasation procedures, toxicity grading and an explicit decision rule for holding, reducing or stopping treatment.
When to Refer
Refer promptly for a suspicious chest image, recurrent or unexplained haemoptysis, persistent or changing cough with concerning features, non-resolving focal pneumonia, unexplained unilateral pleural effusion, hoarseness, clubbing, supraclavicular lymphadenopathy or unexplained weight loss with respiratory symptoms. The referral should include symptom duration, physiological observations, tobacco and occupational history, tuberculosis testing and treatment if any, prior images for comparison, renal function relevant to contrast, anticoagulation, comorbidity and functional status. Repeating antibiotics without a defined reassessment date is not an adequate pathway.
The receiving service should be able to plan CT and the biopsy that yields maximum diagnostic and staging information safely. Central airway compromise, significant haemoptysis, superior vena cava obstruction, hypoxia, rapidly accumulating pleural effusion or neurological compromise requires same-day or emergency escalation. Potentially resectable disease deserves early thoracic surgical and nodal-staging review before an invasive test inadvertently compromises planning. An accessible node or metastatic lesion may sometimes be preferable to lung puncture; the choice belongs to the multidisciplinary team.
After confirmation, refer for complete oncology staging and treatment planning, plus smoking cessation, nutrition, respiratory support, rehabilitation and palliative care according to need. Suspected hereditary predisposition is uncommon but may warrant genetics input in selected very young or syndromic cases. In India, care may pass from a primary or district facility to a medical college, state cancer institute, National Cancer Grid member, charitable centre or private hospital. Confirm whether the destination offers pathology review, molecular testing, thoracic surgery and radiotherapy. Transfer images, slides or blocks and reports; avoid forcing costly repetition. A named navigator, appointment, transport plan and feedback route make the referral clinically real.
Red Flags
Airway, breathing and circulation take priority. Large-volume or ongoing haemoptysis, falling oxygen saturation, respiratory exhaustion, stridor, haemodynamic instability or reduced consciousness requires emergency care. Position and resuscitation follow local emergency protocols while respiratory, interventional radiology and surgical help is mobilised. Facial, neck or upper-limb swelling with venous distension, dyspnoea or headache suggests superior vena cava obstruction. A central tumour can also cause critical airway narrowing or post-obstructive infection; these problems should not await routine staging completion.
New severe back pain, limb weakness, a sensory level, gait deterioration or bladder or bowel dysfunction may indicate metastatic spinal cord compression. New seizure, focal deficit, persistent vomiting, marked confusion or severe headache can indicate intracranial metastasis or metabolic disturbance. Confusion, dehydration, constipation and arrhythmia can accompany hypercalcaemia; disproportionate drowsiness or seizures may occur with hyponatraemia, including paraneoplastic SIADH. These are clinical emergencies requiring laboratory and imaging confirmation, not exam labels applied remotely.
During treatment, fever, rigors, hypotension or sudden deterioration may be neutropenic sepsis. New breathlessness can reflect pulmonary embolism, infection, pneumonitis, radiation injury, pleural effusion, cardiac disease or progression. Immune-related myocarditis or pneumonitis can be rapidly fatal despite subtle early findings. Major infusion reaction, uncontrolled vomiting, severe diarrhoea, jaundice, bleeding or inability to take medicines needs urgent assessment. Psychological crisis, uncontrolled symptoms and inability to access oxygen or analgesia are also red flags. Every treatment plan should specify who to contact, where to attend after hours and which records the patient should carry.
Indian Clinical Context
India combines a substantial tobacco-attributable burden with regional use of bidis and other products, household and outdoor air pollution, occupational exposure and a large tuberculosis burden. The IARC India fact sheet estimated 58,970 new male lung-cancer cases in 2022 and ranked lung cancer second among cancers in men. That sex-specific modelled estimate must not be presented as all-India real-time incidence. Women and never-smokers also develop lung cancer, and their symptoms must not be discounted because they fall outside a stereotyped profile.
Tuberculosis creates a recurring diagnostic hazard. Starting empirical anti-tuberculous treatment may appear accessible, but it can delay cancer diagnosis when microbiological evidence is absent or imaging is atypical. Cancer and TB can coexist, so a positive test does not always close the case. Systems should preserve CT images, pathology blocks, cytology cell blocks and microbiology results and establish a defined review point. Limited tissue is especially costly when repeat travel or biopsy is difficult; sampling strategy should anticipate histology, nodal stage and molecular testing.
Access to PET-CT, EBUS, comprehensive molecular panels, thoracic surgery, modern radiotherapy and newer medicines varies greatly. A guideline can describe these tools without promising them. Resource-aware care prioritises a safe diagnosis, accurate stage, tests that change an available treatment and prompt symptom control. Public schemes, state programmes, charitable support and generic access differ; eligibility must be verified locally. current guidelines supplies useful diagnostic and treatment principles but reflects UK services and commissioning, and parts of its staging framework were developed using an older AJCC edition. Indian teams should use a current local staging manual and approved protocols. Low-dose CT screening is a programme, not an opportunistic single scan; do not import foreign age and pack-year criteria as an Indian national recommendation without a quality-assured pathway for nodule follow-up, diagnosis and treatment.
NMC Competency Mapping
The NMC CBME 2024 curriculum maps undergraduate lung-tumour learning most directly to SU26.4, which addresses aetiology, pathogenesis, clinical features and principles of management of lung tumours. Pathology competencies support the diagnostic chain: PA6.1 addresses neoplasia and spread, PA6.3 carcinogenesis, PA6.4 effects of tumour on the host including paraneoplastic syndromes, PA6.5 laboratory cancer diagnosis and molecular profiles, and PA25.7 gross and microscopic features of lung tumours. These are educational outcomes, not permission to perform bronchoscopy, biopsy, staging or prescribe anticancer therapy independently.
A competent undergraduate should recognise suspicious symptoms, take a quantified tobacco and occupational history, assess physiological urgency and distinguish a symptom-led cancer evaluation from population screening. They should explain why contrast CT precedes biopsy planning in many pathways, why the best biopsy may be a node or metastatic site, and why sufficient tissue is needed for histological and molecular classification. They should distinguish NSCLC from SCLC at a principles level, recognise major histological patterns and connect stage and performance status to curative versus palliative intent without memorising a transient drug algorithm.
Indian clinical reasoning requires explicit TB awareness without anchoring. The learner should request microbiological evidence when infection is plausible, recognise coexistence and plan reassessment if clinical-radiological-pathological findings disagree. They should identify haemoptysis with instability, superior vena cava obstruction, cord compression, brain metastasis, hypercalcaemia, SIADH and neutropenic sepsis as urgent problems. Communication competence includes discussing uncertainty, smoking without blame, the need for tissue, possible treatment burden and palliative care as active care. Skills and decisions remain supervised and protocol-bound.
Key Exam Pearls for NEET PG
Non-small-cell lung cancer includes adenocarcinoma, squamous carcinoma and large-cell or other less common patterns; small-cell carcinoma is a neuroendocrine malignancy with early dissemination and important paraneoplastic associations. Adenocarcinoma is often peripheral and is common in never-smokers. Squamous carcinoma is often central, may cavitate and can produce PTH-related peptide with hypercalcaemia. Small-cell carcinoma can produce ectopic ACTH, SIADH and Lambert-Eaton myasthenic syndrome. A Pancoast tumour at the apex can cause shoulder or arm pain, lower brachial-plexus findings and Horner syndrome.
Persistent haemoptysis, weight loss, recurrent pneumonia in the same region, hoarseness, clubbing and supraclavicular nodes are warning clues. Chest radiography can initiate investigation but does not exclude cancer. Contrast CT defines the lesion and potential spread and guides sampling. Bronchoscopy suits many central lesions; CT-guided biopsy suits selected peripheral lesions; EBUS samples mediastinal or hilar nodes. Sampling an accessible metastasis can establish both diagnosis and stage. Sputum cytology has a limited role and international guidelines reserves it for selected central lesions when more invasive tests are declined or not tolerated.
Do not confuse clinical stage with histological grade. PET-CT helps assess metabolically active nodal or distant disease but inflammatory infection can cause false-positive uptake, particularly relevant in TB-endemic settings. Molecular alteration and PD-L1 testing can direct advanced NSCLC therapy; they do not replace morphology and stage. Early NSCLC may be treated surgically when operable and physiologically fit; definitive radiotherapy is an alternative in selected inoperable disease. SCLC is usually systemic at presentation and is generally treated with systemic therapy plus stage-appropriate radiotherapy. Massive haemoptysis, superior vena cava obstruction, metastatic cord compression, brain-related neurological deterioration, hypercalcaemia and neutropenic sepsis demand urgent action.
Frequently Asked Questions
Can someone who has never smoked still develop lung cancer?
Yes. Smoking is the leading risk factor, but lung cancer also occurs in never-smokers and may be associated with air pollution, occupational exposure, radon, genetic susceptibility or no clearly identified cause. Persistent concerning symptoms or imaging findings require the same diagnostic discipline regardless of smoking history.
Why is tuberculosis testing not enough to exclude lung cancer in India?
Tuberculosis and lung cancer can produce overlapping symptoms and imaging, and they can coexist. Microbiological evidence supports TB diagnosis, while suspicious lesions may still require tissue and staging. Failure to improve, discordant findings or an atypical pattern should trigger prompt multidisciplinary reassessment rather than repeated empirical treatment.
Why is biomarker testing needed after a lung-cancer biopsy?
In advanced non-small-cell lung cancer, validated molecular alterations and immune biomarkers can identify treatments more likely to help and avoid ineffective therapy. The exact tests depend on histology, stage, available treatments and local protocol, so tissue acquisition and preservation must be planned before the first biopsy when possible.
Does palliative care mean that lung-cancer treatment has stopped?
No. Palliative care actively treats pain, breathlessness, cough, fatigue, anxiety and family needs and can run alongside chemotherapy, targeted therapy, immunotherapy or radiotherapy. Early involvement helps clarify goals and manage symptoms; it is not limited to the final days of life or evidence that the team has abandoned treatment.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic